Key result
Administration of digoxin-specific antibody fragments rapidly resolved hyperkalemia, bradycardia, and hemodynamic instability in a patient with digoxin toxicity at therapeutic serum levels.
Why the study?
Literature and guidelines remain inconsistent on whether serum digoxin concentrations should serve as a key criterion for diagnosing digoxin toxicity and indicating digoxin-specific antibody fragments.
Case Report (n=1)
No
Severe, life-threatening digoxin toxicity can occur and be successfully treated with digoxin-specific antibody fragments even when serum digoxin concentrations are within the therapeutic range.
Answers are grounded in this paper and cite their sources.
Case report underscores inconsistent digoxin toxicity criteria; leaves open whether serum levels should determine Fab fragment use.
Introduction: Digoxin is a cardiac glycoside used for rate control in atrial fibrillation and heart failure. Despite its efficacy, digoxin has a narrow therapeutic window and can cause severe side effects, including life-threatening arrhythmias. Literature and guidelines on management of digoxin toxicity remain inconsistent whether to include serum digoxin concentrations as a key criterium for diagnosing digoxin toxicity and determining the indication for digoxin-specific antibody fragments. This report presents a case of digoxin toxicity at therapeutic serum concentrations. Case report: A 76-year-old male presented with bradycardia, hyperkalemia, and acute kidney injury following gastrointestinal bleeding. Despite serum digoxin concentrations within the therapeutic range (1.4 ng/ml), the patient exhibited symptoms consistent with severe digoxin toxicity. Initial treatments, including calcium gluconate, insulin-glucose, and sodium bicarbonate, failed to resolve hyperkalemia and/or bradycardia. Administration of 40 mg digoxin-specific antibody fragments led to rapid normalization of potassium levels, improved heart rate, and hemodynamic stabilization, indicative for severe digoxin toxicity despite therapeutic serum concentrations. Discussion: This case demonstrates that digoxin toxicity can occur at serum concentrations in therapeutic range, emphasizing the importance of clinical features in diagnosing digoxin toxicity. Current guidelines vary on the role of serum digoxin concentrations in guiding the use of digoxin-specific antibody fragments, but this case underscores its efficacy in resolving symptoms related to digoxin toxicity, even at low serum concentrations.
No takes yet. Share an insight, caveat, or question.
Graafsma et al. (2025) conducted a case report in Digoxin toxicity (n=1). Digoxin-specific antibody fragments was evaluated on Clinical improvement (heart rate, potassium levels, hemodynamics). Administration of digoxin-specific antibody fragments rapidly resolved hyperkalemia, bradycardia, and hemodynamic instability in a patient with digoxin toxicity at therapeutic serum levels.
Synapse has enriched 10 related papers. Consider them for comparative context: